• KOL
    • KOLs Community
    • Human
    • Human Papillomavirus
    • Maura L Gillison
    • Maura L Gillison

      Maura L Gillison

      Department of Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX; | The University of Texas MD Anderson Cancer Center. | MD ...



      KOL Resume for Maura L Gillison


      Department of Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX;

      The University of Texas MD Anderson Cancer Center.


      The University of Texas MD Anderson Cancer Center, Houston, TX;

      MD Anderson Cancer Center, Houston, TX, United States


      MD Anderson, Houston, USA


      The University of Texas MD Anderson Cancer Center, Houston, TX USA

      MD Anderson Cancer Center, Houston, Texas


      Johns Hopkins Medical Institute, Baltimore, MD, USA

      Department of Internal Medicine, The Ohio State University, Columbus, Ohio, United States of America

      MD Anderson Cancer Center, Houston, Texas.


      Ohio State University, Columbus, OH.

      Department of Thoracic/Head and Neck Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA

      Carole Fakhry, Johns Hopkins University, Baltimore, MD; Qiang Zhang and Jonathan Harris, NRG Oncology Statistics and Data Management Center, American College of Radiology; John A. Ridge, Fox Chase Cancer Center, Philadelphia, PA; Phuc Felix Nguyen-Tân and Louise Lambert, Centre Hospitalier de l'Université de Montréal, Montreal; Eric Vigneault, L'Hotel-Dieu de Quebec, Ville de Québec, Quebec, Canada; David I. Rosenthal, Randal S. Weber, and Maura L. Gillison, MD Anderson Cancer Center, Houston, TX; Andy M. Trotti III, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; William L. Barrett, University of Cincinnati Cancer Institute, Cincinnati, OH; Wade L. Thorstad, Washington University, St Louis, MO; Christopher U. Jones, Sutter General Hospital, Sacramento; Sue S. Yom, University of California San Francisco, San Francisco; Shyam S.D. Rao, University of California Davis, Davis; Quynh-Thu Le, Stanford University, Stanford, CA; Stuart J. Wong, Medical College of Wisconsin, Milwaukee, WI; James A. Bonner, University of Alabama at Birmingham Medical Center, Birmingham, AL; David Raben, University of Colorado, Aurora, CO; and Mahesh R. Kudrimoti, University of Kentucky, Lexington, KY.


      Ohio State University Comprehensive Cancer Center, Columbus, OH, USA

      Johns Hopkins Medical Institute


      Ohio State Univ, Columbus, OH


      The Ohio State University, Columbus, OH

      Ohio State University Comprehensive Cancer Center, Columbus



      Maura L Gillison: Influence Statistics

      Sample of concepts for which Maura L Gillison is among the top experts in the world.
      Concept World rank
      bilateral nonfamilial n1 #1
      diagnosis hpvpositive hnscc #1
      hpvpositive n188 #1
      hpvpositive osccs contrast #1
      screening testing procedures #1
      moderate predictive diagnosis #1
      host genome structure #1
      hnscc hpv infection #1
      45 cancers #1
      control patients odds #1
      reduced clearance 95 #1
      rinses survival #1
      bot malignancy #1
      hpv typespecific infection #1
      cancer female head #1
      oscc diagnosis treatment #1
      rectal scc immunosuppression #1
      diagnosis nontumor types #1
      role hpv16 #1
      vaginal sex partners #1
      hpvpositive cancer #1
      candidate2 16 humans #1
      hpvnegative hnscc diagnosis #1
      30second rinse #1
      multiple myeloma researchers #1
      92 hpvpositive oscc #1
      hpv transmission partners #1
      hpv genomic #1
      hiv‐infected youth #1
      patients hpv osccs #1
      time hpvpositive hnscc #1
      viral attribution #1
      treatment hpvopc #1
      hpv partners #1
      hpvpositive hpvnegative oscc #1
      pathology characterization detection #1
      pretreatment leukocytosis status #1
      cytopathologic abnormality #1
      hpv positive epidermis #1
      0129 0522 #1
      oropharyngeal abnormalities pap2 #1
      large natural studies #1
      cancers version #1
      oral hpv acquisition #1
      increase oropharynx #1
      years tobacco #1
      rectal anal scc #1
      hnscc rates #1
      95 lscc #1
      436 consecutive cases #1


      Prominent publications by Maura L Gillison

      KOL-Index: 25936

      BACKGROUND: Patients with platinum-refractory recurrent or metastatic squamous cell carcinoma of the head and neck have few treatment options and poor prognosis. Nivolumab significantly improved survival of this patient population when compared with standard single-agent therapy of investigator's choice in Checkmate 141; here we report the effect of nivolumab on patient-reported outcomes (PROs).

      METHODS: CheckMate 141 was a randomised, open-label, phase 3 trial in patients with recurrent ...

      Known for Nivolumab Patients | Cell Carcinoma | Checkmate 141 | Investigators Choice | Metastatic Squamous
      KOL-Index: 23496

      BACKGROUND: Patients with human papillomavirus (HPV)-positive oropharyngeal squamous cell carcinoma have high survival when treated with radiotherapy plus cisplatin. Whether replacement of cisplatin with cetuximab-an antibody against the epidermal growth factor receptor-can preserve high survival and reduce treatment toxicity is unknown. We investigated whether cetuximab would maintain a high proportion of patient survival and reduce acute and late toxicity.

      METHODS: RTOG 1016 was a ...

      Known for Cisplatin Cetuximab | Patients Radiotherapy | Human Papillomavirus | Oropharyngeal Cancer | Rtog 1016
      KOL-Index: 19116

      BACKGROUND: The improved prognosis for patients with human papillomavirus (HPV)-positive head and neck squamous cell carcinoma (HNSCC) relative to HPV-negative HNSCC observed in retrospective analyses remains to be confirmed in a prospective clinical trial.

      METHODS: We prospectively evaluated the association of tumor HPV status with therapeutic response and survival among 96 patients with stage III or IV HNSCC of the oropharynx or larynx who participated in an Eastern Cooperative ...

      Known for Human Papillomavirus | Patients Hnscc | Positive Head | Cell Carcinoma | Prospective Clinical Trial
      KOL-Index: 19115

      CONTEXT: Human papillomavirus (HPV) infection is the principal cause of a distinct form of oropharyngeal squamous cell carcinoma that is increasing in incidence among men in the United States. However, little is known about the epidemiology of oral HPV infection.

      OBJECTIVE: To determine the prevalence of oral HPV infection in the United States.

      DESIGN, SETTING, AND PARTICIPANTS: A cross-sectional study was conducted as part of the National Health and Nutrition Examination Survey (NHANES) ...

      Known for United States | Oral Hpv Infection | Prevalence Women | Sexual Partners | 69 Years
      KOL-Index: 17138

      BACKGROUND: Patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after platinum chemotherapy have a very poor prognosis and limited therapeutic options. Nivolumab, an anti-programmed death 1 (PD-1) monoclonal antibody, was assessed as treatment for this condition.

      METHODS: In this randomized, open-label, phase 3 trial, we assigned, in a 2:1 ratio, 361 patients with recurrent squamous-cell carcinoma of the head and neck whose disease had progressed within 6 ...

      Known for Standard Therapy | Cell Carcinoma | Patients Nivolumab | Neck Treatment | Recurrent Squamous
      KOL-Index: 15458

      IMPORTANCE: Human papillomavirus-related oropharyngeal carcinoma (HPV-OPC) is increasing in incidence in the United States. Although HPV-OPC has favorable prognosis, 10% to 25% of HPV-OPCs recur. Detection of human papillomavirus (HPV) DNA in oral rinses is associated with HPV-OPC, but its potential as a prognostic biomarker is unclear.

      OBJECTIVE: To determine whether HPV DNA detection in oral rinses after treatment for HPV-OPC is associated with recurrence and survival.

      DESIGN, SETTING, ...

      Known for Human Papillomavirus | Oral Rinses | Hpv Dna | United States | Recurrent Disease
      KOL-Index: 15449

      Tumor human papillomavirus (HPV) status is a prognostic factor for oropharyngeal cancer, but classification methods are not standardized. Here we validate the HPV classification methods used in US cooperative group trials. Tumor DNA and RNA purified from 240 paraffin-embedded oropharyngeal cancers diagnosed from 2000 to 2009 were scored as evaluable if positive for DNA and mRNA controls by quantitative polymerase chain reaction (PCR). Eighteen high-risk (HR) HPV types were detected in ...

      Known for Hpv Status | Messenger Rna | Sensitivity Specificity | Oropharyngeal Cancer | Oncogene Proteins
      KOL-Index: 15201

      PURPOSE: To report results of a randomized phase II trial (Radiation Therapy Oncology Group RTOG-0234) examining concurrent chemoradiotherapy and cetuximab in the postoperative treatment of patients with squamous cell carcinoma of the head and neck (SCCHN) with high-risk pathologic features.

      PATIENTS AND METHODS: Eligibility required pathologic stage III to IV SCCHN with gross total resection showing positive margins and/or extracapsular nodal extension and/or two or more nodal ...

      Known for Postoperative Chemoradiotherapy | Squamous Cell | Cetuximab Patients | Head Neck | Cisplatin Arm
      KOL-Index: 15139

      PURPOSE: A significant proportion of oropharyngeal squamous cell carcinomas (OSCC) are associated with the human papilloma virus (HPV), particularly HPV16. The optimal method for HPV determination on archival materials however, remains unclear. We compared a quantitative real-time polymerase chain reaction (qRT-PCR) assay for HPV16 mRNA to a DNA in situ hybridization (ISH) method, and evaluated their significance for overall (OS) and disease-free (DFS) survival.


      Known for Hpv16 E6 | Oropharyngeal Squamous | Situ Hybridization | Patients Oscc | Oncogene Proteins
      KOL-Index: 14881

      BACKGROUND: High-risk types of human papillomavirus (HPV), including HPV-16, cause a subgroup of head and neck squamous cell carcinomas (HNSCCs). We examined whether the risk factors for HPV-16-positive HNSCCs are similar to those for HPV-16-negative HNSCCs in a hospital-based case-control study.

      METHODS: Case subjects (n = 240) diagnosed with HNSCC at the Johns Hopkins Hospital from 2000 through 2006 were stratified by tumor HPV-16 status as determined by in situ hybridization. Two ...

      Known for Negative Head | Neck Cancers | Human Papillomavirus | Tobacco Smoking | Alcohol Drinking
      KOL-Index: 14720

      PURPOSE: Combining cisplatin or cetuximab with radiation improves overall survival (OS) of patients with stage III or IV head and neck carcinoma (HNC). Cetuximab plus platinum regimens also increase OS in metastatic HNC. The Radiation Therapy Oncology Group launched a phase III trial to test the hypothesis that adding cetuximab to the radiation-cisplatin platform improves progression-free survival (PFS).

      PATIENTS AND METHODS: Eligible patients with stage III or IV HNC were randomly ...

      Known for Neck Carcinoma | Stage Iii | Cisplatin Cetuximab | Pfs Patients | Female Head
      KOL-Index: 14584

      PURPOSE: Cetuximab, which modulates immune responses, may affect the efficacy of subsequent immunotherapy. Here, we assessed outcomes with nivolumab, by prior cetuximab exposure, in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) who had experienced progression within 6 months of platinum-containing chemotherapy.

      PATIENTS AND METHODS: In the randomized, open-label, phase III CheckMate 141 trial, patients were randomized 2:1 to nivolumab 3 ...

      Known for Prior Cetuximab | Nivolumab Patients | Squamous Cell | Head Neck | Antineoplastic Agents
      KOL-Index: 14335

      PURPOSE: We tested the efficacy and toxicity of cisplatin plus accelerated fractionation with a concomitant boost (AFX-C) versus standard fractionation (SFX) in locally advanced head and neck carcinoma (LA-HNC).

      PATIENTS AND METHODS: Patients had stage III to IV carcinoma of the oral cavity, oropharynx, hypopharynx, or larynx. Radiation therapy schedules were 70 Gy in 35 fractions over 7 weeks (SFX) or 72 Gy in 42 fractions over 6 weeks (AFX-C). Cisplatin doses were 100 mg/m(2) once ...

      Known for Neck Carcinoma | Concurrent Cisplatin | Standard Fractionation | Radiation Therapy | Female Head
      KOL-Index: 14224

      PURPOSE: To better understand oral human papillomavirus (HPV) infection and cancer risk among long-term sexual partners of patients with HPV-positive oropharyngeal cancer (HPV-OPC).

      PATIENTS AND METHODS: An oral rinse sample, risk factor survey, cancer history, and oral examination (partners only) were collected from patients with HPV-OPC and their partners. Oral rinse samples were evaluated for 36 types of HPV DNA using PGMY 09/11 primers and line-blot hybridization and HPV16 copy ...

      Known for Oropharyngeal Cancer | Partners Patients | Oral Hpv | Human Papillomavirus | Infections Prevalence

      Key People For Human Papillomavirus

      Top KOLs in the world
      Chris J L M Meijer
      cervical cancer human papillomavirus hpv dna
      Keerti V Shah
      human papillomavirus cervical cancer simian virus
      Nubia Muñoz
      cervical cancer human papillomavirus hpv dna
      Mark H Schiffman
      human papillomavirus costa rica cervical cancer
      Peter J F Snijders
      human papillomavirus cervical cancer hpv dna
      Francesc Xavier Bosch
      cervical cancer human papillomavirus hpv types

      Maura L Gillison:Expert Impact

      Concepts for whichMaura L Gillisonhas direct influence:Human papillomavirus,  United states,  Squamous cell,  Oropharyngeal cancer,  Head neck,  Oral hpv,  Cell carcinoma,  Hpv infection.

      Maura L Gillison:KOL impact

      Concepts related to the work of other authors for whichfor which Maura L Gillison has influence:Human papillomavirus,  Squamous cell,  Head neck,  Oropharyngeal cancer,  Hpv infection,  Oral cavity,  United states.



      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

      Department of Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX; | The University of Texas MD Anderson Cancer Center. | MD Anderson Cancer Center, Houston, TX | Thoracic/Head and Neck Medical Oncology

    Download on the App StoreGet it on Google Play

    Copyright © 2023 - KOL means Key Opinion Leaders .

    KOL does not provide medical advice, diagnosis or treatment.